Eptotermin alfa
As of the edition of 20 October 2026, Eptotermin alfa is a protein: withdrawn from the market in 2016; acts on ACVR1, BMPR1A and BMPR1B and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Withdrawn from market, 2016
- Kind
- Protein
- Withdrawn from market
- 1 July 2016 (in some regions)
- Registered trials
- 1, 0 stopped early
- Disease areas
- Bones, joints and muscles
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| All trials | 1 |